Professional services
UnclaimedA public-private global health partnership that expands access to vaccines and strengthens immunization systems in lower-income countries.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Gavi, the Vaccine Alliance, is an international public-private partnership established in 2000 to increase access to life-saving vaccines in low-income and other eligible countries. It was created as a successor to the Children's Vaccine Initiative and brings together governments, the World Health Organization, UNICEF, the World Bank, vaccine manufacturers, research institutions, civil-society organizations, philanthropists and private-sector partners. Its headquarters are in Geneva, Switzerland, and its work is carried out through country-led immunization programs rather than through a conventional commercial operating model. Gavi raises funds from donor governments, foundations and other partners, then uses those resources to co-finance vaccines, negotiate procurement arrangements and support delivery infrastructure. Its assistance has included routine childhood immunization, introduction of newer vaccines, cold-chain equipment, health-worker training, data and supply systems, and emergency responses. Countries receiving support are generally expected to contribute an increasing share of vaccine costs as their economies develop, with the long-term objective of transitioning from external support to domestically financed programs. A central part of Gavi's model is market shaping. By aggregating demand from many countries and offering manufacturers longer-term purchasing commitments, the alliance seeks to reduce prices, stabilize supply and encourage production of vaccines for diseases that may otherwise be commercially unattractive. Its advance market commitment for pneumococcal vaccines was designed to stimulate supply while setting conditions for lower-income-country procurement. Gavi has also used pooled purchasing and supplier competition in programs involving pentavalent, human papillomavirus, meningococcal A, rotavirus, measles-rubella and other vaccines. The alliance reports that it has helped immunize hundreds of millions of children and contributed to preventing millions of deaths. It has also supported the introduction of many vaccines that were previously unavailable or unaffordable in poorer countries. During the COVID-19 pandemic, Gavi became one of the leading organizations in COVAX, the international mechanism intended to support equitable access to COVID-19 vaccines, particularly for countries with limited purchasing power. Gavi's approach has been praised for combining public financing, technical expertise and private-sector capabilities in a relatively focused, results-oriented structure. It has also attracted criticism. Civil-society groups and academic commentators have questioned the influence of private donors and pharmaceutical companies in governance, the emphasis on newer and more expensive vaccines, the level of subsidies paid to large manufacturers, procurement transparency, and whether health-system-strengthening funding is sufficiently broad or sustainable. Médecins Sans Frontières has repeatedly challenged vaccine pricing and the structure of the pneumococcal advance market commitment. Gavi has responded by emphasizing pooled procurement, competition, price differentiation, country ownership and efforts to improve sustainability. Gavi operates through successive five-year strategies and replenishment cycles. Its 2026–2030 Gavi 6.0 strategy emphasizes reaching under-immunized children, strengthening country-led and sustainable immunization programs, improving vaccine markets and preparing for future health emergencies. It is not a publicly listed company, does not sell vaccines directly to consumers, and has no conventional corporate owner.
History
Gavi emerged from the Children's Vaccine Initiative, a collaboration launched in 1990 to improve the delivery of childhood vaccines in developing countries. It was formally established in 2000 as the Global Alliance for Vaccines and Immunization, with support from governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry and the Bill & Melinda Gates Foundation. The founding model sought to combine public-health legitimacy with private-sector financing, procurement expertise and measurable performance goals. During its first years, Gavi concentrated on increasing coverage of routine childhood vaccines and helping countries introduce newer products. Its financing model combined grants, country co-financing and donor commitments arranged in multi-year cycles. Longer funding horizons allowed the alliance to negotiate larger purchasing agreements with manufacturers and to give suppliers more predictable demand. Gavi also supported vaccine delivery systems, including logistics, cold chains, surveillance, health-worker training and immunization data. A continuing institutional debate concerned whether Gavi should remain narrowly focused on vaccines or fund broader health-system strengthening. Supporters of the broader approach argued that immunization cannot be sustained where clinics lack staff, transport, refrigeration, reliable financing or reporting capacity. Critics within and outside the organization worried that broad health-system work could dilute Gavi's measurable vaccine mandate. In 2005, Gavi adopted a health-system-strengthening objective, although later assessments found that much of the related spending remained closely tied to immunization operations and infrastructure. The organization subsequently placed greater emphasis on sustainability and country ownership. Gavi's market-shaping role became more explicit in the 2010s. It used pooled purchasing, supplier competition, price differentiation and advance market commitments to influence vaccine supply. The pneumococcal advance market commitment, backed by donor funds, sought to encourage manufacturers to develop and supply suitable vaccines for poorer countries. The arrangement helped expand access but became controversial when MSF and other critics argued that GSK and Pfizer received substantial public subsidies while prices remained too high. The debate highlighted a recurring tension in Gavi's model: manufacturers need predictable revenue and incentives to supply difficult markets, while public-health advocates seek the lowest sustainable prices and wider competition. Gavi also worked on stabilizing the market for pentavalent vaccines and supported the introduction of vaccines against pneumococcal disease, rotavirus, human papillomavirus, meningococcal A and other diseases. Its programs contributed to the expansion of immunization in countries where governments could not initially finance complete vaccine programs themselves. The alliance has reported that its work has reached hundreds of millions of children and helped avert millions of deaths, although attribution of population-level health outcomes is complex and depends on national health systems and other partners. In 2014, the organization changed its public name and identity, moving from GAVI Alliance to Gavi, the Vaccine Alliance. Its profile grew substantially during the COVID-19 pandemic. In 2020, Gavi helped lead COVAX alongside the World Health Organization and the Coalition for Epidemic Preparedness Innovations. COVAX was intended to pool procurement and support more equitable distribution of COVID-19 vaccines, particularly for countries unable to compete with wealthy governments for early supplies. Gavi also financed delivery readiness, including cold-chain equipment and technical support. Gavi continues to operate through five-year strategic and replenishment cycles. Its 2026–2030 Gavi 6.0 strategy places greater emphasis on reaching zero-dose and under-immunized children, strengthening sustainable national programs, improving vaccine markets and preparing for future pandemics. The alliance remains dependent on donor commitments and must balance ambitious global coverage goals with changing geopolitical support, domestic co-financing requirements, vaccine prices, manufacturing capacity and criticism concerning governance and accountability.
- 2024
Gavi 6.0 is approved
[3]The Board approves the 2026–2030 strategy, centered on sustainable national immunization systems and reaching missed children.
- 2020
Gavi helps establish COVAX
[5]Gavi becomes a leading organization in the global COVID-19 vaccine allocation and financing mechanism.
- 2020
Pneumococcal vaccine price reaches $2 per dose in a UNICEF agreement
[1]A procurement agreement involving the Serum Institute of India lowers the stated price for pneumococcal conjugate vaccine supplied through the Gavi-supported mechanism.
- 2014
The organization adopts the Gavi name
[1]The former GAVI Alliance rebrands as Gavi, the Vaccine Alliance, with a new visual identity.
- 2011
Market shaping is added to the strategy
[1]Gavi makes the development of stable, competitive vaccine markets an explicit strategic priority.
- 2010
Pneumococcal advance market commitment begins
[1]Gavi's advance market commitment supports the development and supply of pneumococcal conjugate vaccines for eligible countries.
- 2005
Health-system strengthening becomes a formal objective
[1]Following internal debate, Gavi adopts a goal of improving the capacity of integrated health systems to deliver immunization.
- 2000
Gavi is founded
[1]The Global Alliance for Vaccines and Immunization is created as a public-private partnership focused on vaccine access in poor countries.
- 1990
Children's Vaccine Initiative is launched
[1]The predecessor initiative that helped establish the institutional and policy foundations for Gavi begins work on improving childhood immunization in developing countries.
Products and positioning
A global health partnership using donor financing, pooled procurement and public-private coordination to improve equitable vaccine access.
Immunization program · 2000
Routine immunization support
Gavi finances and technically supports national childhood immunization programs in eligible countries. Assistance can cover vaccine procurement, delivery planning, data systems, supervision, training, outreach and co-financing arrangements. The purpose is to increase coverage of essential vaccines while helping governments build programs that can eventually be sustained with domestic resources.
Vaccine access program · 2000
New vaccine introduction
This program helps eligible countries introduce vaccines that have historically been too expensive or difficult to deliver at scale. Supported products have included pneumococcal, rotavirus, human papillomavirus, meningococcal A and measles-rubella vaccines. Gavi combines financing, procurement, technical support and delivery preparation rather than manufacturing the vaccines itself.
Market-shaping mechanism · 2010
Pneumococcal Advance Market Commitment
The pneumococcal AMC uses donor-backed purchase commitments to encourage manufacturers to supply suitable vaccines for low-income countries. It was intended to reduce market uncertainty, accelerate availability and establish a lower tail price. The mechanism expanded supply but also generated criticism concerning manufacturer subsidies, prices and the level of competition.
Health-system support · 2005
Health-system strengthening
Gavi has funded activities intended to make immunization systems more reliable, including cold chains, transport, health-worker capacity, planning, supervision and information systems. The scope and effectiveness of this work have been debated, with critics arguing that grants sometimes focused on short-term immunization inputs rather than wider primary-care reform or durable national systems.
Pandemic vaccine access · 2020
COVAX support
Through COVAX, Gavi supported pooled COVID-19 vaccine procurement, financing and delivery readiness for participating countries. The work included assistance with cold-chain capacity, technical preparation and allocation arrangements intended to reduce the gap between wealthy countries and countries with limited ability to purchase vaccines directly.
Controversies
2019
Pneumococcal vaccine pricing and supplier concentration
MSF argued that Gavi's pneumococcal procurement arrangements relied too heavily on GSK and Pfizer and that public subsidies had not produced sufficiently low prices. The issue also raised broader questions about pharmaceutical influence and governance conflicts.
2016
Debate over health-system-strengthening grants
Academic and civil-society assessments questioned whether Gavi's health-system funding was broad, sustainable and aligned with recipient-country priorities. Critics cited reporting burdens, short-term spending and a narrow reliance on vaccination coverage as a principal performance measure.
2012
Criticism of new-vaccine priorities
Médecins Sans Frontières criticized Gavi for directing substantial resources toward newer and more expensive vaccines while millions of children still lacked basic vaccines.
Marketing campaigns
- 2020Global Vaccine Summit
Global donor community
A donor summit hosted by the United Kingdom mobilized approximately $8.8 billion for Gavi's 2021–2025 funding cycle, exceeding the stated target.
Outcome. Funding target exceeded.
- 2020COVAX
Global · with emphasis on low- and middle-income countries
Gavi helped lead the international effort to pool COVID-19 vaccine procurement and support more equitable allocation and delivery. It created a major multilateral channel for COVID-19 vaccine access, although global supply constraints and unequal early distribution remained significant challenges.
Outcome. Created a major multilateral channel for COVID-19 vaccine access, although global supply constraints and unequal early distribution remained significant challenges.
- 2016A Fair Shot
Global vaccine-access debate
Médecins Sans Frontières used the A Fair Shot campaign to press GSK, Pfizer and Gavi to lower pneumococcal vaccine prices for poorer countries. The campaign intensified public debate over vaccine pricing and procurement; later procurement arrangements involving the Serum Institute offered lower prices.
Outcome. The campaign intensified public debate over vaccine pricing and procurement; later procurement arrangements involving the Serum Institute offered lower prices.
Brand decisions
2024
Approve Gavi 6.0StrategyBackground
Gavi's next strategic period required a stronger focus on missed children, country ownership, sustainable financing and pandemic preparedness.
Action taken
The Board approved the 2026–2030 strategy, including goals for sustainable, country-led immunization programs.
Aftermath
Implementation depends on donor replenishment, national co-financing and the alliance's ability to reach zero-dose and under-immunized children.
2020
Support the COVAX FacilityProduct launchBackground
The COVID-19 pandemic created a risk that wealthy countries would secure vaccine supplies while poorer countries were excluded from early access.
Action taken
Gavi joined the WHO and CEPI in leading a pooled international mechanism for vaccine procurement, financing and allocation.
Aftermath
COVAX became a central channel for COVID-19 vaccine distribution, though manufacturing constraints and national purchasing deals limited its ability to eliminate inequity.
2011
Make market shaping a strategic priorityStrategyBackground
Vaccine prices, supply instability and limited manufacturer incentives constrained access in eligible countries.
Action taken
Gavi added the shaping of vaccine and immunization-supply markets to its strategic goals.
Aftermath
The alliance expanded pooled procurement, supplier competition and long-term purchasing arrangements.
2010
Launch the pneumococcal Advance Market CommitmentOtherBackground
Pneumococcal disease was a major cause of child mortality, while manufacturers faced uncertainty about demand and affordability in poorer markets.
Action taken
Donor-backed commitments were used to encourage supply of qualifying pneumococcal vaccines, with GSK and Pfizer receiving support under the mechanism.
Aftermath
The program expanded access but faced sustained criticism over public subsidies, supplier concentration and prices.
AMC subsidy allocations. US$225 million allocated to each of GSK and Pfizer (2010–2011)
- Médecins Sans Frontières — MSF argued that procurement should make greater use of lower-cost suppliers and that the mechanism transferred too much value to large pharmaceutical companies.
2005
Adopt a health-system-strengthening objectiveStrategyBackground
Debate focused on whether vaccine coverage could be sustained without improvements in staffing, logistics, transport, financing and primary-care capacity.
Action taken
Gavi endorsed a goal of strengthening integrated health systems capable of delivering immunization.
Aftermath
The objective remained contested, and later analyses concluded that much of the spending was concentrated on immunization-related inputs rather than broad health-system reform.
Recent events
Reported
Bharat Biotech agrees to reduce Mosqivac price[7]
Bharat Biotech said it reached an equitable pricing agreement with Gavi and UNICEF to reduce the price of its Mosqivac malaria vaccine by about 40%, to €5.50 per dose from early 2027.
Reported
Clover Biopharmaceuticals signs COVAX pre-purchase agreement[8]
Clover Biopharmaceuticals signed a pre-purchase agreement with Gavi to provide up to 414 million doses of its recombinant protein COVID-19 vaccine candidate for distribution through COVAX. Initial deliveries are conditional on the candidate receiving WHO emergency-use listing.
- Unconfirmed
TikTok pledges $10 million to Gavi for immunisation efforts in Africa[9]
TikTok said it would donate US$10 million to Gavi for immunisation efforts in Africa; the Bill and Melinda Gates Foundation would match the contribution, bringing the total support to US$20 million.
Sources10 sources
- 1GAVIen.wikipedia.org
- 2Gavi official websitegavi.org
- 3Gavi strategygavi.org
- 4Gavi fundinggavi.org
- 5COVAX Facilitygavi.org
- 6Gavi leadershipgavi.org
- 7Bharat Biotech 同意下调 Mosqivac 疫苗价格timesofindia.indiatimes.com
- 8三叶草生物与Gavi签署COVAX预购协议finance.sina.com.cn
- 9TikTok承诺向Gavi捐赠1000万美元支持非洲免疫工作thisdaylive.com
- 10Bharat Biotech announces equitable pricing for Malaria Vaccine RTS,S/AS01biospectrumindia.com
Cite this profile: Cite the canonical profile. /brand-wiki/gavi · Editorial policy · How profiles are compiled